Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP1093212.RActP8-VzvFKUmxk-oE1NIxR0o8J_0pi8e3vV8UAXYjO8130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093212.RActP8-VzvFKUmxk-oE1NIxR0o8J_0pi8e3vV8UAXYjO8130_provenance.
• NP407931.RArcIpJ7rVbKDJcCC52IAdfcTUbbVucCtpSDnH7uyMHTE130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407931.RArcIpJ7rVbKDJcCC52IAdfcTUbbVucCtpSDnH7uyMHTE130_provenance.
• NP873152.RApQyOastPfhleEKX0Ocw8xK9PXvWaGalvO7L8FXG03LY130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873152.RApQyOastPfhleEKX0Ocw8xK9PXvWaGalvO7L8FXG03LY130_provenance.
• NP913978.RAtg1-eyusoSX_kKBQk69JaKPFemBmDXi6yzOiRdi9KhU130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913978.RAtg1-eyusoSX_kKBQk69JaKPFemBmDXi6yzOiRdi9KhU130_provenance.
• NP1093216.RAk3F3ooukSsuS4ENPTFuVuOlyMzkFPG_WftRF9nj_G9I130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093216.RAk3F3ooukSsuS4ENPTFuVuOlyMzkFPG_WftRF9nj_G9I130_provenance.
• NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_provenance.
• NP605947.RA-gjmlJnF4ncH7_YgvyI6XQ92SB_xwUk2SKoFR1HP0Tw130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605947.RA-gjmlJnF4ncH7_YgvyI6XQ92SB_xwUk2SKoFR1HP0Tw130_provenance.
• NP1093210.RAJI3kIV9C45EZfhK2ba_RXLDQ_C0vBOjglRpD1Nnv9mw130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093210.RAJI3kIV9C45EZfhK2ba_RXLDQ_C0vBOjglRpD1Nnv9mw130_provenance.
• NP1093217.RAE6jIJVjH6Ps5cu0fN_XZDBmyt4ss1toZ_I-Xxh3BLto130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093217.RAE6jIJVjH6Ps5cu0fN_XZDBmyt4ss1toZ_I-Xxh3BLto130_provenance.
• NP781392.RAyikEBtK_QjjZNdriiPoz2vp9Y5hCjLe9D6N_RbURgsg130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781392.RAyikEBtK_QjjZNdriiPoz2vp9Y5hCjLe9D6N_RbURgsg130_provenance.
• NP978487.RAwP1GCtYOEcYoVcUZ0RsZDDb54YJm49AZbwPYgELyTXQ130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978487.RAwP1GCtYOEcYoVcUZ0RsZDDb54YJm49AZbwPYgELyTXQ130_provenance.
• NP1093211.RA8gSfuaPImfT3eGvexLjh2WLCXlGR3zwijYpz3Ds2Hyo130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093211.RA8gSfuaPImfT3eGvexLjh2WLCXlGR3zwijYpz3Ds2Hyo130_provenance.
• NP1093213.RA0GDk_vEzCSt_nxvwKe5OFHKlSPocj12R9x-i9ssfz1s130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093213.RA0GDk_vEzCSt_nxvwKe5OFHKlSPocj12R9x-i9ssfz1s130_provenance.
• NP1093215.RA0FkHJe0ypmmCKvsoRIYIDDBGjxeD2C5CiBe2St2Oz2Y130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093215.RA0FkHJe0ypmmCKvsoRIYIDDBGjxeD2C5CiBe2St2Oz2Y130_provenance.